Halozyme Therapeutics, Inc.(HALO) Stock Research - Grey Stern Research
Loading...

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

$59.94 (2.08%)

HALO Financial Performance


Use the table below to view Halozyme Therapeutics, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $58.47 -
52 Week Low $33.15 -
52 Week High $65.53 -
Market Cap $7.4 Billion 10/22
Gross Margin 75% 13/22
Profit Margin 40% 3/22
EBITDA margin 59% 1/22
Q2 - 2024 Revenue $231.4 Million 6/22
Q2 - 2024 Earnings $93.2 Million 5/22
Q2 - 2024 Free Cash Flow $53.2 Million 4/22
Trailing 4 Quarters Revenue $873.3 Million 6/22
Trailing 4 Quarters Earnings $337.3 Million 5/22
Quarterly Earnings Growth 25% 9/22
Annual Earnings Growth 74% 5/22
Quarterly Revenue Growth 5% 13/22
Annual Revenue Growth 23% 8/22
Cash On Hand $187.9 Million 16/22
Short Term Debt $30.7 Million 8/22
Long Term Debt $1.5 Billion 2/22

Halozyme Therapeutics, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Halozyme Therapeutics, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 22.05 2/22
PS 8.52 14/22
PB 25.70 3/22
PC 39.60 6/22
Liabilities to Equity 5.80 3/22
ROA 0.17 5/22
ROE 1.17 5/22
Current Ratio 1.17 18/22
Quick Ratio 0.31 21/22
Long Term Debt to Equity 5.19 3/22
Debt to Equity 5.30 3/22
Burn Rate -7.37 22/22
Cash to Cap 0.03 14/22
CCR 0.57 13/22
EV to EBITDA 63.84 3/22
EV to Revenue 10.06 11/22

Company Details

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

CEO: Dr. Helen Torley

Website: https://www.halozyme.com

Address: 11388 Sorrento Valley Rd San Diego, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Halozyme Therapeutics, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Halozyme Therapeutics, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $34.2 Billion
BioMarin Pharmaceutical Inc. BMRN $12.6 Billion
Insmed Incorporated INSM $12.4 Billion
Exelixis, Inc. EXEL $9.9 Billion
BeiGene, Ltd. BGNE $22.9 Billion
Seagen Inc. SGEN $43.2 Billion
Ultragenyx Pharmaceutical Inc. RARE $4.8 Billion
Protagonist Therapeutics, Inc. PTGX $2.7 Billion
Blueprint Medicines Corporation BPMC $6.2 Billion
Cytokinetics, Incorporated CYTK $6.2 Billion
Agios Pharmaceuticals, Inc. AGIO $2.7 Billion
Apellis Pharmaceuticals, Inc. APLS $3.4 Billion
Ascendis Pharma A/S ASND $7.3 Billion
Alector, Inc. ALEC $486.1 Million
Larimar Therapeutics, Inc. LRMR $469.6 Million
Legend Biotech Corporation LEGN $8.2 Billion
Cerevel Therapeutics Holdings, Inc. CERE $8.2 Billion
Inhibrx, Inc. INBX $227.4 Million
Edgewise Therapeutics, Inc. EWTX $3.4 Billion
Viridian Therapeutics, Inc. VRDN $1.8 Billion
DICE Therapeutics, Inc. DICE $2.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
HALO Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 231.4 Million $93.2 Million
Q1 2024 $ 195.9 Million $76.8 Million
Q4 2023 $ 230.0 Million $85.4 Million
Q3 2023 $ 216.0 Million $81.8 Million
Q2 2023 $ 221.0 Million $74.8 Million
Q1 2023 $ 162.1 Million $39.6 Million
Q4 2022 $ 181.5 Million $57.7 Million
Q3 2022 $ 209.0 Million $61.6 Million

View All

HALO Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $187.9 Million $2.0 Billion $1.5 Billion $289.4 Million
Q1 2024 $164.6 Million $1.8 Billion $1.5 Billion $177.8 Million
Q4 2023 $118.4 Million $1.7 Billion $1.5 Billion $83.8 Million
Q3 2023 $274.2 Million $1.9 Billion $1.5 Billion $249.2 Million
Q2 2023 $221.2 Million $1.8 Billion $1.5 Billion $151.0 Million
Q1 2023 $96.4 Million $1.7 Billion $1.5 Billion $65.9 Million
Q4 2022 $234.2 Million $1.8 Billion $1.5 Billion $169.8 Million
Q3 2022 $147.2 Million $1.9 Billion $1.5 Billion $97.0 Million

View All

HALO Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $53.2 Million -$2.6 Million $23.2 Million
Q1 2024 $125.9 Million -$3.5 Million $46.3 Million
Q4 2023 $99.8 Million -$2.6 Million -$155.9 Million
Q3 2023 $129.5 Million -$2.9 Million $53.1 Million
Q2 2023 $68.5 Million $1.6 Million $124.3 Million
Q1 2023 $75.6 Million -$11.4 Million -$137.8 Million
Q4 2022 $80.1 Million -$2.3 Million $87.0 Million
Q3 2022 $115.9 Million -$1.5 Million $56.2 Million

View All